Ibandronic Acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574740

CAS#: 114084-78-5

Description: Ibandronic Acid is a bisphosphonate anti-resorptive agent and bone resorption inhibitor.

Price and Availability

Size Price Shipping out time Quantity
1g USD 250 2 Weeks
5g USD 550 2 Weeks
10g USD 900 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-21. Prices are subject to change without notice.

Ibandronic Acid, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 574740
Name: Ibandronic Acid
CAS#: 114084-78-5
Chemical Formula: C9H23NO7P2
Exact Mass: 319.095
Molecular Weight: 319.23
Elemental Analysis: C, 33.86; H, 7.26; N, 4.39; O, 35.08; P, 19.41

Synonym: Ibandronic Acid; BPH 24; Ibandronate

IUPAC/Chemical Name: P,P'-[1-Hydroxy-3-(methylpentylamino)propylidene]bisphosphonic Acid


InChi Code: InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1. McCormack PL, Plosker GL. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer. Drugs. 2006;66(5):711-728. doi:10.2165/00003495-200666050-00011

2. Barrett-Lee P, Casbard A, Abraham J, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial [published correction appears in Lancet Oncol. 2014 Feb;15(2):e52-3]. Lancet Oncol. 2014;15(1):114-122. doi:10.1016/S1470-2045(13)70539-4